Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV 1 Infection Clear all
Terminated Phase 2 Interventional Results available

A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1

NCT00824369
View directory record Official record
Conditions
HIV-1
Interventions
No drug will be administered
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Sacramento, California • Miami, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 2 Interventional

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

NCT00008463
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
24
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations

NCT00002398
View directory record Official record
Conditions
HIV Infections
Interventions
Levocarnitine, Adefovir dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

NCT02345707
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Cabotegravir 30 mg current formulation, Cabotegravir 30 mg micronized new formulation 500 M, Cabotegravir 30 mg unmicronized new formulation 500 U, Cabotegravir 30 mg micronized new formulation 650 M, Cabotegravir 30 mg unmicronized new formulation 650 U
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2015 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 1 Interventional

Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity

NCT00000977
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
2
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Completed No phase listed Observational

Neurodevelopmental and Neurological Study of Infants and Children With HIV-1 Infection and AIDS in Clinical Trials

NCT00000759
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 8 Years
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Not applicable Interventional

An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml

NCT00002172
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Immunogen
Biological
Lead sponsor
The Immune Response Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

NCT01667731
View directory record Official record
Conditions
Hepatitis C, Human Immunodeficiency Virus
Interventions
SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 27, 2026, 4:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations

NCT00001681
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

NCT00001119
View directory record Official record
Conditions
HIV Infections
Interventions
Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Hepatitis B Vaccine (Recombinant), Lamivudine, Zidovudine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
11
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Metformin During Nicotine Withdrawal

NCT03593538
View directory record Official record
Conditions
Smoking, HIV-1-infection
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Not listed Phase 1 Interventional

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)

NCT03588715
View directory record Official record
Conditions
HIV, HIV/AIDS, HIV-1 Infection
Interventions
Pegylated Interferon alpha 2b (peg-IFN-α2b), 3BNC117 + 10-1074
Drug
Lead sponsor
Luis Montaner
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Protease Inhibitors

NCT00774735
View directory record Official record
Conditions
Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions
GSK1349572
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2010 · Synced Sep 27, 2026, 4:56 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Cannabis Use, Cognition, and the Endocannabinoid System in HIV

NCT04883255
View directory record Official record
Conditions
HIV-1-infection
Interventions
10 mg Δ9-tetrahydrocannabinol (THC), 600 mg cannabidiol (CBD), Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 27, 2026, 4:56 AM EDT
Terminated Phase 1 Interventional Results available

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

NCT05458102
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions
Vesatolimod, Cobicistat, Voriconazole, Rifabutin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Long Beach, California • Miami, Florida • West Palm Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Not applicable Interventional

Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen

NCT00014937
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir, lamivudine/zidovudine, efavirenz, lamivudine, stavudine, zidovudine, didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
32
States / cities
Los Angeles, California • Denver, Colorado • Farmington, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2013 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 2 Interventional

Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)

NCT00002079
View directory record Official record
Conditions
HIV Infections
Interventions
Butyldeoxynojirimycin, Zidovudine
Drug
Lead sponsor
G D Searle
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
San Francisco, California • Tarzana, California • Miami Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 4:56 AM EDT
Terminated Phase 1 Interventional

Study of GS-1219 in Participants With HIV-1

NCT07115368
View directory record Official record
Conditions
HIV-1-infection
Interventions
GS-1219, BVY, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

NCT02422797
View directory record Official record
Conditions
HIV Infections
Interventions
DTG 50 mg, RPV 25 mg, CAR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
13
States / cities
Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 2 Interventional

An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

NCT00081588
View directory record Official record
Conditions
HIV Infection
Interventions
TMC114
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
26
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 2 Interventional

A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy

NCT00000820
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Not applicable Interventional

Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs

NCT00016588
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 1 Interventional

A Study of DPC 817 in HIV-Infected Males

NCT00040274
View directory record Official record
Conditions
HIV Infections
Interventions
DPC 817
Drug
Lead sponsor
Pharmasset
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 18, 2005 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 2 Interventional

Effects of Changing HIV Therapy at Lower Versus Higher Viral Loads

NCT00036465
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment regimen change
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
23
States / cities
Menlo Park, California • Stanford, California • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2013 · Synced Sep 27, 2026, 4:56 AM EDT